Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies

INTRODUCTION: Anaemia is a common complication of chronic kidney disease (CKD). Owing to the limitations of erythropoiesis-stimulating agents (ESAs), the current standard of care, there is a need to develop new therapies. Hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors might be a pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Hiroyasu, Taguchi, Megumi, Matsuda, Yoshimi, Iekushi, Kazuma, Yamada, Takashi, Akizawa, Tadao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Renal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6588957/
https://www.ncbi.nlm.nih.gov/pubmed/31203242
http://dx.doi.org/10.1136/bmjopen-2018-026704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6588957/
https://www.ncbi.nlm.nih.gov/pubmed/31203242
http://dx.doi.org/10.1136/bmjopen-2018-026704

Ejemplares similares